Sunday, March 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
No Result
View All Result

Ivermectin doesn’t prevent severe disease from Covid-19, new study finds

Daily Remedy by Daily Remedy
February 19, 2022
in
0

The antiparasitic drug ivermectin doesn’t prevent severe disease from Covid-19 any more effectively than symptom management and close observation by medical professionals, according to a study published Friday in the journal JAMA Internal Medicine.

The study enrolled nearly 500 people 50 and older who were at risk of severe Covid-19 because of their age and underlying health. These patients were treated at 20 public hospitals and a quarantine center in Malaysia in 2021.

Half of the patients took a relatively high dose of oral ivermectin for five days, and the other half — the comparison group — received treatment for their symptoms, such as fever-reducing medications. All were monitored for progression of disease.

Source: CNN

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Most employers are unknowingly steering their health plans toward higher costs and reduced control — until they understand how fiduciary missteps and anti-competitive contracts bleed their budgets dry. Katie Talento, a recognized health policy leader, reveals how shifting the network paradigm can save millions by emphasizing independent providers, direct contracting, and innovative tiering models. Grounded in real-world case studies like Harris Rosen’s community-driven initiative, this episode dives deep into practical strategies to realign incentives—focusing on primary care, specialty care, and transparent vendor relationships. You'll discover how traditional carrier networks are often Trojan horses, locking employers into costly, opaque arrangements that undermine fiduciary duties. Katie breaks down simple yet powerful reforms: owning your data, eliminating conflicts of interest, and outlawing anti-competitive contract clauses. We explore how a post-network framework—where patients are free to choose providers without restrictive network barriers—can massively reduce costs and improve health outcomes. You'll learn why independent, locally owned providers are vital to rebuilding trust, reducing unnecessary procedures, and reinvesting savings into the community. This conversation offers clarity on the unseen legal landmines employers face and actionable ways to craft health plans built on transparency, independence, and aligned incentives. Perfect for HR pros, benefits advisors, physicians, and employer leaders committed to transforming healthcare from the ground up. If you’re tired of broken healthcare models draining your budget and frustrating your staff, this episode will empower you to take control by understanding and reshaping the very foundations of employer-sponsored health. Discover the blueprint for smarter, fairer, and more sustainable benefits. Visit katytalento.com or allbetter.health to connect directly and explore how these innovations can work for your organization. Your path toward a healthier, more cost-effective future starts here. Chapters 00:00 Introduction to Employer-Sponsored Health Plans 02:50 Understanding ERISA and Fiduciary Responsibilities 06:08 The Misalignment of Clinical and Financial Interests 08:54 Enforcement and Legal Implications for Employers 11:49 Redefining Networks: The Post-Network Framework 25:34 Navigating Healthcare Contracts and Cash Payments 27:31 Understanding Employer Health Plan Structures 28:04 The Role of Benefits Advisors in Health Plans 30:45 Governance and Data Ownership in Health Plans 37:05 Case Study: The Rosen Hotels' Health Model 41:33 Incentivizing Healthy Choices in Healthcare 47:22 Empowering Primary Care and Independent Providers
The Hidden Costs Employers Don’t See in Traditional Health Plans
YouTube Video xhks7YbmBoY
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

by Daily Remedy
March 1, 2026
0

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!

Twitter Updates

No Result
View All Result

© 2026 Daily Remedy